Diversifying the Anti-Infective Franchise A primary focus for Basilea has been executing the objective to replenish its pipeline and provide longevity beyond the expected loss of exclusivity for its lead antifungal, Cresemba, in late 2027. While Cresemba continues to deliver exceptional performance—with global in-market sales exceeding $560m in 2024—the company is successfully transitioning to a multi-asset model. Basilea's update today highlights progress made in 2025 and what to expect...

Our research note today highlights the opportunities available from Basilea's existing portfolio and pipeline. Basilea addresses the...

The H1 period at Basilea was notable for another strong performance from the anti-fungal Cresemba (isavuconazole). Underlying growth was...